Canada could save an estimated $280 million a year in drug costs if biosimilar uptake here reached the levels seen in Norway, a speaker told attendees at a recent event in Calgary. “One problem with biosimilars is their uptake,” Andrea Staruch, a pharmacy services consultant at Green Shield Canada, said during a presentation at Benefits […]
From drug pooling to medical marijuana, plan sponsors have a number of issues to keep track of when it comes to their benefits plans. At the Face to Face Drug Plan Management forum in Vancouver this month, a panel of experts tackled some of the hot topics the industry is thinking about. Pooling: One concern […]
Green Shield Canada is rolling out a new biosimilar transition program as a pilot project through the first half of 2018, with an aim to extending it to all of its employer clients by the end of the year. The program, which was designed to help plan members transition from an originator drug to a corresponding biosimilar, will initially focus […]
From biosimilars to product listing agreements, a panel of experts tackled some of the hottest topics in drug plan management at the Face to Face Drug Plan Management forum on Dec. 14. Barbara Martinez, who heads up the national drug benefits solutions practice at the Great-West Life Assurance Co., addressed the question of biosimilars during […]
Canadian physicians are becoming more familiar with biosimilars, according to a new survey by the U.S.-based Alliance for Safe Biologic Medicines. The organization’s new survey, which polled more than 400 Canadian prescribers of biologics from 13 therapeutic specialties, found 83 per cent of respondents are either familiar or very familiar with biosimilars, compared to 58 per cent […]